A recent meeting of a global group of ophthalmic experts (Vision Academy Steering Committee) identified four key principles for the ideal treatment regimen for anti-VEGF management of retinal diseases, including maximizing and maintaining visual acuity (VA) benefits for all patients, deciding when to treat next, rather than whether to treat now, titrating the treatment intervals to match patients’ needs and treating at each monitoring visit [12]. Here, VEGFA is linked to Abnormal retinal morphology.